Troponin Testing and Early MI Discharge
Sixth-generation high-sensitivity cardiac troponin T assay classifies more patients below a low-risk threshold at presentation.
-
By
-
Kathryn Wighton
-
June 1, 2026
-
Clinical Scorecard: Troponin Testing and Early MI Discharge
At a Glance
| Category | Detail |
|---|
| Condition | Non-ST-segment elevation myocardial infarction (MI) |
| Key Mechanisms | High-sensitivity cardiac troponin T concentrations |
| Target Population | Adults with suspected non-ST-segment elevation MI |
| Care Setting | Secondary and tertiary hospitals |
Key Highlights
- 61% of patients had sixth-generation troponin T concentrations < 13 ng/L at presentation.
- 8% of patients met the primary outcome of type 1, 4b, or 4c MI or cardiac mortality within 30 days.
- The sixth-generation assay showed a negative predictive value of 99.9% and sensitivity of 99.4%.
- 41% of patients identified as low risk using the sixth-generation assay compared to 17% with the fifth-generation assay.
- The sixth-generation assay reduced the need for serial troponin testing (23% vs 43%).
Guideline-Based Recommendations
Diagnosis
- Utilize sixth-generation high-sensitivity cardiac troponin T for assessing MI risk.
Management
- Consider early discharge for low-risk patients identified by the sixth-generation assay.
Monitoring & Follow-up
- Monitor cardiac troponin T levels as part of MI assessment.
Risks
- Potential for misclassification of low risk in female patients.
Patient & Prescribing Data
Predominantly White adults, median age 59 years, 38% female.
Implementation of the sixth-generation assay may facilitate earlier discharge.
Clinical Best Practices
- Validate the sixth-generation assay in diverse cohorts.
- Conduct prospective studies to confirm findings.
Related Resources & Content
